- 684. Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study.
2021
,Journal: Prostate Cancer and Prostatic Diseases.
Reference: Accepted for publication, March 2021 - 683. Antidiabetic drugs and prostate cancer prognosis in a Finnish population-based cohort.
2021
,Journal: Cancer Epidemiol Biomarkers Prev
Reference: Mar 2; cebp.0580.2019. - 682. Antiepileptic drugs and prostate cancer risk in the Finnish Randomized study of Screening for Prostate Cancer.
2021
,Journal: Int J Cancer
Reference: Feb 26. doi: 10.1002/ijc.33535. - 681. Prognostic index for predicting prostate cancer survival in a randomized screening trial: Development and validation.
2021
,Journal: Cancers
Reference: 13(3), 435; https://doi.org/10.3390/cancers13030435. - 680. Impact of cancer screening on metastasis: a prostate cancer case study
2021
,Journal: J Med Screen
Reference: Feb 9;969141321989738 - 679. Prostate cancer risk prediction using a polygenic risk score
2020
,Journal: Accepted to Sci Rep September 2020
Reference: - 678. Number of screening rounds attended and incidence of high-risk prostate cancer in the Finnish randomized study of screening for prostate cancer (FinRSPC)
2020
,Journal: Accepted to Cancer August 2020
Reference: - 677. Antihypertensive drug use and prostate cancer-specific mortality in Finnish men
2020
,Journal: PLoS One
Reference: Jun 29;15(6):e0234269 - 676. Long-term Health-Related Quality of Life among men with prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer
2020
,Journal: Cancer Med
Reference: 9(15):5643-5654 - doi: 10.1002/cam4.3181. - 675. Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: results of the French section of European Randomized study of Screening for Prostate Cancer (ERSPC)
2020
,Journal: Prog Urol
Reference: Apr;30(5):252-260. - 674. Patients’ education level and treatment modality for prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer.
2020
,Journal: Eur J Cancer
Reference: Mar 28;130:204-210. - 673. Long-term outcomes for men in a Prostate Screening Trial with an Initial Benign Prostate Biopsy: a Population-based Cohort
2019
,Journal: Eur Urol Oncol
Reference: 2019 Nov;2(6):716-722. doi: 10.1016/j.euo.2019.01.016. - 672. Influence of regular aspirin intake on PSA values, prostate cancer incidence and overall survival in a prospective screening trial (ERSPC Aarau)
2019
,Journal: World J Urol
Reference: Doi: 10.1007/s00345-019-03054-5 - 671. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
2019
,Journal: PLOS ONE
Reference: https://doi.org/10.1371/journal.pone.0224479 - 670. Anticoagulants and cancer mortality in the Finnish randomized study of screening for prostate cancer.
2019
,Journal: Cancer Causes & Control
Reference: (2019) 30:877-888. - 669. The impact of design and performance in prostate-specific antigen screening: differences between ERSPC centers.
2019
,Journal: European Urology
Reference: 76 (2019):276-279. - 668. Predicting biochemical recurrence and prostate cancer-specific mortality after radical prostatectomy: comparison of six prediction models in a cohort of patients with screening- and clinically detected prostate cancer.
2019
,Journal: BJU International
Reference: doi:10.1111/bju.14790 - 667. Charlson comorbidity index based on hospital episode statistics performs adequately in predicting mortality, but its discriminative ability diminishes over time.
2019
,Journal: Clinical Epidemiology
Reference: 11:923-932. - 666. Prediction of high-grade prostate cancer following multiparametric magnetic resonance imaging: improving the Rotterdam European Randomized study of Screening for Prostate Cancer Risk Calculators
2019
,Journal: Eur Urol
Reference: 2019 Feb;75(2):310-318. - 665. The ERSPC study: quality takes time and perseverance
2019
,Journal: Clin Chem
Reference: 2019 Jan; 65(1):208-209 - 664. Results of prostate cancer screening in a unique cohort at 19yr of follow-up
2019
,Journal: Eur Urol
Reference: 2019 Mar;75(3):374-377 - 663. Could differences in treatment between trial arms explain the reduction in prostate cancer mortality in the European Randomized study of Screening for Prostate cancer?
2019
,Journal: Eur Urol
Reference: 2019 Mar 27. pii: S0302-2838(19)30196-4. doi: 10.1016/j.eururo.2019.03.010. - 662. A 16-year follow-up of the European Randomized study of Screening for Prostate Cancer
2019
,Journal: Eur Urol
Reference: 2019 Feb 26. pii: S0302-2838(19)30150-2. doi: 10.1016/j.eururo.2019.02.009. - 661. Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: analysis of the Finnish randomized study of screening for prostate cancer.
2019
,Journal: Int J Cancer
Reference: 2019 Jan 17. doi:10.1002/ijc.32129 - 660. Allopurinol and the risk of prostate cancer in a Finnish population-based cohort.
2019
,Journal: Prostate Cancer Prostatic Dis
Reference: 2019 Jan 29. doi:10.1038/s41391-019-0129-2. - 659. Antihypertensive drugs and prostate cancer risk in a Finnish population-based cohort.
2018
,Journal: Scand J Urol
Reference: 2018 Oct-Dec;52(5-6):321-327. - 658. The number of screening cycles needed to reduce prostate cancer mortality in the Finnish section of the European Randomized Study of Prostate Cancer (ERSPC).
2019
,Journal: Clin Cancer Res
Reference: 2019 Jan 15;25(2):839-843. doi:10.1158/1078-0432. CCR-18-1807 - 657. Synergistic interaction of HOXB13 and CIP2A predisposes to aggressive prostate cancer.
2018
,Journal: Clin Cancer Res
Reference: 2018 Dec 15;24(24):6265-6276 - 656. Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men.
2018
,Journal: Sci rep
Reference: Jul 9;8(1):10308 - 655. Prostate cancer screening: what can we learn from randomised trials?
2018
,Journal: Transl Androl Urol
Reference: Feb;7(1):12-17 - 654. Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
2018
,Journal: Br J Cancer
Reference: 2018 May;118(9):1248-1254 - 653. What is an acceptable false negative rate in the detection of prostate cancer?
2018
,Journal: Transl Androl Urol
Reference: Feb;7(1):54-60 - 652. Screening for prostate cancer: are organized screening programs necessary?
2018
,Journal: Transl Androl Urol
Reference: Feb;7(1):4-11 - 651. Editorial Comment to Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
2018
,Journal: Int J Urol
Reference: Mar;25(3):277 - 650. Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data.
2018
,Journal: Eur J Cancer
Reference: Apr;93:108-118 - 649. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort.
2017
,Journal: Prostate Cancer Prostatic Dis
Reference: Dec 22. - 648. Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
2017
,Journal: Int J Urol
Reference: Mar;25(3):270-276 - 647. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.
2017
,Journal: Eur Urol Focus
Reference: Nov 11. pii: S2405-4569(17)30258-4 - 646. Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use
2017
,Journal: J Urol
Reference: Aug;198(2):305-309 - 645. Prostate cancer screening in Europe and Asia.
2017
,Journal: Asian J Urol
Reference: Apr;4(2):86-95 - 644. Summary statement on screening for prostate cancer in Europe.
2018
,Journal: Int J Cancer
Reference: Feb 15;142(4):741-746 - 643. Stopping screening, when and how?
2018
,Journal: Transl Androl Urol
Reference: Feb;7(1):46-53 - 642. Real-time Watchful Surveillance Looks Like Active Waiting.
2017
,Journal: Eur Urol
Reference: Dec;72(6):908-909 - 641. Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer.
2017
,Journal: Mod Pathol
Reference: Aug;30(8):1126-1132 - 640. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
2016
,Journal: Eur Urol Focus
Reference: Aug 4. pii: S2405-4569(16)30107-9 - 639. Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.
2018
,Journal: Scand J Urol
Reference: Feb;52(1):27-37 - 638. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.
2018
,Journal: Cancer
Reference: Mar 15;124(6):1197-1206 - 637. Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging?
2017
,Journal: Eur Urol
Reference: Jun 21. pii: S0302-2838(17)30514-6 - 636. Additional benefit of using a risk-based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
2017
,Journal: BJU Int
Reference: Sep;120(3):394-400 - 635. Biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam.
2017
,Journal: Int J Urol
Reference: Apr;24(4):281-286